Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta
Data supports M281’s potential to prevent placental transfer of disease-inducing antibodies from mother to fetus in alloimmune and autoimmune diseases of the fetus and newborn    Global multi-center Phase 2 study of M281 in hemolytic disease of the fetus and newborn (HDFN) now active following
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
-- Ended 2018 with a cash position of $449.0 million -- -- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN) underway; First healthy volunteer dosed in Phase 1/2 trial of M254 in immune thrombocytopenia (ITP) -- CAMBRIDGE, Mass. , Feb.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting
Study highlights ability of M281 to inhibit transfer of immunoglobulin G from maternal to fetal circulation in ex vivo placental perfusion model M281 currently being evaluated in an international Phase 2 study in Hemolytic Disease of the Fetus and Newborn (HDFN) CAMBRIDGE, Mass. , Feb.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G
CAMBRIDGE, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the dosing of the first subject in the Phase 1/2
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler , President and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference .  The presentation is scheduled for Wednesday, January 9, 2019 at 10:00 a.m.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
CAMBRIDGE, Mass. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced the closing of its
View HTML
Toggle Summary UPDATE: Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced the pricing of its
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , Dec. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced that it is commencing an
View HTML
Toggle Summary Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®
CAMBRIDGE, Mass. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory
View HTML